ClinicalTrials.gg
RecruitingNCT07444203TRIDENT 2Updated Mar 2, 2026

Transformative Research in Diabetic Nephropathy 2.0

An observational study in Diabetic Nephropathies, Kidney Diseases and Renal Insufficiency, Chronic, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by University of Pennsylvania · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Planned enrollment
15th of 31
200 · median 175
Started
2025
with 5 others
Observational
31 of 153
9 open now
Primary completion
2027-05
later than 16 of 30 live
Registered
152nd of 153
by date

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 15th largest by planned enrollment of the 31 observational ones that give a count, is one of 6 that started in 2025, is one of 31 observational ones, reaches primary completion later than 16 of the 30 other live ones, and was the 152nd registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care.

The main questions this study aims to answer are:

  • Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them?
  • Are these kidney tissue patterns linked with how kidney health changes over time?

Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines.

Participants will:

Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time

Read the detailed description

TRIDENT 2.0 is a multicenter observational translational study that characterizes kidney molecular and histopathologic features in relation to exposure to kidney-protective therapies, with a focus on sodium-glucose cotransporter-2 (SGLT2) inhibitors. The study leverages archived clinical kidney pathology material and harmonized clinical data to support integrated molecular-histologic analyses across participating sites.

Tissue sources and central repository workflows:

Formalin-fixed, paraffin-embedded (FFPE) kidney tissue sections/slides are generated from archived clinical pathology material (including clinically indicated kidney biopsies and available donor or nephrectomy specimens) and transferred under coded identifiers to a central repository for downstream molecular assays and digital pathology.

Spatial transcriptomics and molecular profiling:

Spatially resolved transcriptomic methods are used to generate high-resolution molecular maps while preserving tissue architecture. FFPE (or fresh-frozen, when available) sections may be processed using commercially available spatial transcriptomics platforms (e.g., 10x Genomics Visium, NanoString CosMx, Xenium) or updated technologies implemented under study governance. Standard quality control procedures evaluate tissue integrity, RNA quality, capture efficiency, and resolution of major kidney compartments and cell types. Sequencing is performed on Illumina platforms with platform-appropriate depth, followed by preprocessing using platform-specific pipelines and downstream analysis in R/Python workflows (e.g., Seurat or equivalent) with normalization and batch correction as needed. Planned analyses include identification of cell-type and sub-cell-type signatures in spatial context, mapping of injury patterns (e.g., fibrosis/inflammation/vascular remodeling), and comparative molecular profiling across disease categories and therapy exposure groups with adjustment for relevant covariates.

Digital pathology and centralized histopathology review:

Digitized clinical stains and available diagnostic images are used for centralized review and standardized lesion scoring by renal pathologists. When applicable, diabetic kidney disease (DKD) is classified using established renal pathology criteria. Specimen adequacy metrics are used to guide analytic inclusion and sensitivity analyses.

Linked clinical data (high level):

Clinical data are harmonized across sites to support clinicopathologic and molecular integration, including medication exposure history and relevant laboratory and diagnostic variables. Longitudinal clinical information is used to contextualize molecular and histologic findings for downstream modeling.

Statistical and integrative analytic approach:

Analytic methods include differential expression and pathway analyses with appropriate multiple-testing control and covariate adjustment. Integrative modeling may combine molecular, histologic, and clinical domains using dimension reduction and regularized approaches to derive molecular signatures associated with disease state and therapy exposure.

03

Conditions studied

  • Diabetic Nephropathies
  • Kidney Diseases
  • Renal Insufficiency, Chronic
  • Diabetes Mellitus, Type 2

Keywords

  • Diabetic nephropathy
  • Chronic kidney disease
  • Diabetic kidney disease
  • Sodium-glucose cotransporter 2 inhibitors
  • Spatial transcriptomics
  • Kidney-protective therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

TRIDENT 2.0 will enroll approximately 200 participants across multiple sites. Eligible participants include:

  • Patients with diabetic kidney disease (DKD) confirmed by clinically indicated biopsy.
  • Patients with other kidney diseases (disease controls).
  • Living kidney donors (donor biopsy tissue).
  • Patients undergoing nephrectomy (non-tumor, adjacent normal tissue when available).

All participants must provide informed consent for release of one H\&E slide from their clinical biopsy or surgical specimen and for abstraction of relevant clinical data.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • ≥10 ml/min/1.73 m2 based on the 2021 race-free CKD-EPI equation13
  • Underwent a clinically indicated kidney , living donor biopsy, or nephrectomy (non-tumor adjacent tissue available).
  • Able and willing to provide for release of one pathology and clinical data abstraction.

Exclusion criteria

Exclusion Criteria:

  • Inability to provide .
  • Archived or surgical tissue unavailable for slide preparation.
  • Any local institutional policy that prohibits release of H\&E slides for research.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Biopsy-confirmed Diabetic Kidney Disease Cohort

    Adults with diabetic kidney disease confirmed by a clinically indicated kidney biopsy. This cohort is used to evaluate kidney molecular and histopathologic features in relation to medication exposure history. Interventions/exposures of interest (observational): Primary exposure is sodium-glucose cotransporter 2 inhibitors; additional therapy exposures of interest include renin-angiotensin-aldosterone system blockade, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and other therapies.

    Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)

  • Disease Control Kidney Disease Cohort

    Adults with other forms of kidney disease (non-DKD), included as disease controls for cross-disease comparisons of molecular and histologic patterns. Interventions/exposures of interest (observational): Medication exposure history is captured to support comparisons across therapy classes, including SGLT2 inhibitors and other disease-modifying therapies.

    Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)

  • Living Kidney Donor Cohort

    Living kidney donors with available donor biopsy tissue, included as a comparator group to provide reference kidney tissue profiles. Interventions/exposures of interest (observational): Medication exposure history (including kidney-protective therapies where applicable) may be used in descriptive and comparative analyses; donors primarily serve as a reference/control tissue cohort.

    Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)

  • Nephrectomy Control Cohort

    Adults undergoing nephrectomy with non-tumor, adjacent normal kidney tissue available, included as a control/reference tissue cohort. Interventions/exposures of interest (observational): Medication exposure history (including SGLT2 inhibitors and other kidney-protective therapies) may be incorporated in comparative analyses across cohorts.

    Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)

Interventions

  • DrugSGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard-of-care exposure to sodium-glucose cotransporter 2 inhibitors documented from medication history. Participants are not assigned therapy. Exposure status is used for observational comparisons of kidney tissue molecular and histopathologic features.

    Also known as: SGLT2 inhibitors

  • DrugRenin-angiotensin-aldosterone system blockade

    Standard-of-care exposure to renin-angiotensin-aldosterone system blockade documented from medication history for observational comparisons.

  • DrugGLP-1 receptor agonistsStudies of GLP-1 receptor agonistsGLP-1 receptor agonists pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard-of-care exposure documented from medication history for observational comparisons.

    Also known as: GLP-1 receptor agonists

  • Standard-of-care exposure documented from medication history for observational comparisons.

    Also known as: MRAs

06

What researchers measure

Primary outcomes

  1. Change in Kidney Tissue molecular fingerprint

    Change/differences in kidney tissue molecular "fingerprint" (molecular pathways / spatial gene expression signatures derived from archived kidney tissue) comparing participants exposed to sodium-glucose cotransporter 2 inhibitors versus controls and participants on other therapies. Tissue profiling includes single-cell spatial transcriptomics with differential expression and pathway analyses stratified by therapy exposure.

    Time frame: Baseline enrollment to 18 months.

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR)

    Change in eGFR calculated using the 2021 race-free CKD-EPI equation.

    Time frame: Baseline to 18 months

  2. Change in urine protein/creatinine ratio

    Change in urine protein/creatinine ratio over follow-up.

    Time frame: Baseline to 6 months.

  3. Descriptive histopathology features and spatial gene expression patterns across cohorts

    Descriptive histopathological features (fibrosis, sclerosis, inflammation, vascular changes) and spatial gene expression patterns evaluated across diabetic kidney disease, disease controls, donor, and nephrectomy cohorts.

    Time frame: At enrollment/baseline (Single assessment on the archived clinical specimen slide)

  4. Associations between histopathological features and clinical outcomes

    Associations between histopathological features and clinical outcomes including eGFR slope, proteinuria, kidney failure, and transplant.

    Time frame: Up to 3 years (longitudinal outcome abstraction, including dialysis/transplant/kidney failure/mortality as captured).

  5. Associations between histopathological features and prior medication exposures

    Associations between histopathological features and prior medication exposures, including SGLT2 inhibitors, renin-angiotensin-aldosterone system blockade, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and other therapies.

    Time frame: Baseline (prior/current medication exposure history at enrollment).

  6. Feasibility metrics

    Accrual rate by cohort, proportion of slides successfully retrieved, and slide quality metrics.

    Time frame: During study accrual and specimen acquisition (up to 3 years).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 38 observational studies under Diabetic Nephropathies, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 25. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Nov 12, 2025
Primary completionEst.
May 30, 2027
CompletionEst.
Nov 12, 2028
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07444203
Responsible party
Katalin Susztak (MD, PhD, University of Pennsylvania) — Principal investigator
First posted
Mar 2, 2026
Start date
Nov 12, 2025
Primary completion
May 30, 2027 (estimated)
Completion
Nov 12, 2028 (estimated)
Last update
Mar 2, 2026

Study contacts

Gaia Coppock, MD
Contact
Gaia.Coppock@pennmedicine.upenn.edu
2673030158
Mohammed Al Dulaimee, BS
Contact
mohammed.aldulaimee@pennmedicine.upenn.edu
5853589733
Katalin Susztak, MD, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion